For example, several erlotinib derivatives were able to reduce CIP2A levels and increase PP2A activity in breast cancer and hepatocellular carcinoma cells via disrupting the interaction between the transcription factor Elk1 and the CIP2A promotor (138, 139). This evidence concerns the gene CIP2A and breast carcinoma.